UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions

Advances in Urology, 2014-01, Vol.2014 (2014), p.134-139

2014

Volltextzugriff (PDF)

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

World journal of urology, 2017-03, Vol.35 (3), p.367-378

2017

Volltextzugriff (PDF)

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria

ESMO open, 2024-09, Vol.9 (9), p.103725, Article 103725

2024

Volltextzugriff (PDF)

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

ESMO open, 2024-05, Vol.9 (5), p.102994, Article 102994

2024

Volltextzugriff (PDF)

Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy

Current molecular medicine, 2012-11, Vol.12 (9), p.1125-1141

2012

Volltextzugriff (PDF)

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2021-03, Vol.384 (9), p.829-841

2021

Volltextzugriff (PDF)

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible

Annals of oncology, 2016-10, Vol.27, p.vi267-vi267

2016

Volltextzugriff (PDF)

A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors

Annals of oncology, 2016-10, Vol.27, p.vi266-vi266

2016

Volltextzugriff (PDF)

A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)

Annals of oncology, 2016-10, Vol.27, p.vi272-vi272

2016

Volltextzugriff (PDF)

Impact of lenalidomide on the antiproliferative effect of gemcitabine/carboplatin (GC) and gemcitabine/cisplatin (GP) against urothelial carcinoma (UC) cells in vitro

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15164-e15164

2011

Volltextzugriff (PDF)

Rapidly Progressing Urothelial Carcinoma Due to a Rare TP53 (p.Arg110Pro) Mutation: A Case Report and Review of the Literature

Research and reports in urology, 2021-01, Vol.13, p.181-184

2021

Volltextzugriff (PDF)

Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4566-4566

2011

Volltextzugriff (PDF)

A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.171-171

2011

Volltextzugriff (PDF)

Vascular thromboembolic events in patients (pts) with advanced urothelial cancer (UC) treated with carboplatin/gemcitabine alone or in combination with bevacizumab

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5074-5074

2009

Volltextzugriff (PDF)

A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.163-163

2011

Volltextzugriff (PDF)

Phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy-naive patients (Pts) with advanced/metastatic urothelial carcinoma (UC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.248-248

2011

Volltextzugriff (PDF)

A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15070-e15070

2011

Volltextzugriff (PDF)

Peripheral-blood gene expression profiling in bladder cancer (BC) patients (pts)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5076-5076

2008

Volltextzugriff (PDF)

Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4574-4574

2011

Volltextzugriff (PDF)

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

The lancet oncology, 2018-01, Vol.19 (1), p.51-64

2018

Volltextzugriff (PDF)

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2117-2124

2017

Volltextzugriff (PDF)

Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review

Cancer treatment reviews, 2022-02, Vol.103, p.102333-102333, Article 102333

2022

Volltextzugriff (PDF)

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

The lancet oncology, 2022-07, Vol.23 (7), p.888-898

2022

Volltextzugriff (PDF)

The value of IMmotion010 for rare kidney cancer histologies

The Lancet (British edition), 2023-07, Vol.402 (10397), p.181-181

2023

Volltextzugriff (PDF)

1 – 25 von 275

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(260)
Mit Volltextzugriff
(239)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(113)
Life Sciences & Biomedicine
(105)
Humans
(89)
Oncology
(68)
Male
(45)
Aged
(35)
Female
(35)
Urology & Nephrology
(33)
Middle Aged
(31)
Bladder Cancer
(30)
Immunotherapy
(28)
Metastasis
(21)
Urinary Bladder Neoplasms - Pathology
(20)
Adult
(19)
Tumors
(19)
Antineoplastic Agents - Therapeutic Use
(17)
Chemotherapy
(17)
Urothelial Carcinoma
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Aged, 80 And Over
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible

A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors

A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)

Impact of lenalidomide on the antiproliferative effect of gemcitabine/carboplatin (GC) and gemcitabine/cisplatin (GP) against urothelial carcinoma (UC) cells in vitro

Rapidly Progressing Urothelial Carcinoma Due to a Rare TP53 (p.Arg110Pro) Mutation: A Case Report and Review of the Literature

Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC)

A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC)

Vascular thromboembolic events in patients (pts) with advanced urothelial cancer (UC) treated with carboplatin/gemcitabine alone or in combination with bevacizumab

A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC)

Phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy-naive patients (Pts) with advanced/metastatic urothelial carcinoma (UC)

A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC)

Peripheral-blood gene expression profiling in bladder cancer (BC) patients (pts)

Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review

Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

The value of IMmotion010 for rare kidney cancer histologies

Suchergebnisse filtern